Polaris Partners — 2022 Investments
10 investments dated 2022 · listed companies and verified rows first · show all
BiotechWaltham, US
Tillman U. Gerngross(Executive Officer, Director)Lynn Connolly(Executive Officer)Eric Kimble(Executive Officer)Halley Gilbert(Executive Officer)Rebecca Dabora(Executive Officer)Ellie Hershberger(Executive Officer)
Board seatTerry McGuireTerrance G. McGuire· per SEC Form D · $23.7M raise · filed Nov 2022
Co-investorsMithril Capital ManagementVeltro Argento
BiotechCambridge, US
JOSH MANDEL-BREHM(Executive Officer, Director)RICHARD YOUNG(Director)
BoardMICHAEL HIGGINS(Director)JORGE CONDE(Director)in
Board seatAmir Nashat· per SEC Form D · filed Jun 2022
Co-investors5AM VenturesAndreessen HorowitzLongwood Fund
Fractyl develops therapies for obesity and type 2 diabetes, focusing on non-drug-based approaches rooted in understanding metabolic disease mechanisms.
BiotechHealthtechMedical DevicesLexington, US
HARITH RAJAGOPALAN(Executive Officer, Director)JAY CAPLAN(Executive Officer, Director)Harith Rajagopalan(Executive Officer, Director)inLISA DAVIDSON(Executive Officer)Ajay Royan(Director)Christopher Gabrieli(Director)
Board seatAmy Schulman· per SEC Form D · $20.1M raise · filed Jan 2022
Co-investorsBessemer Venture PartnersCatalio Capital Management, LPEmergent Medical Partners, LLPMithril Capital ManagementVeltro Argento
US agricultural biotech that discovered microbe-based crop protection products; its assets were sold to Certis Biologicals and Ginkgo Bioworks in 2024.
AgTechResearch Triangle Park, US
Scott Uknes(Manager)Eric Ward(Manager)Paul Schulze-Lefert(President)Michael Koziel(Vice President and Manager)
BoardThomas Dietz(Manager)Kristina Burow(Manager)in
Board seatAmir Nashat· per SEC Form D · $117.2M raise · filed Feb 2022
Co-investorsAliment CapitalBlue Horizon CorporationPontifax AgTechARCH Venture PartnersNovalis LifeSciences
HealthtechWaltham, US
Tillman Gerngross(Executive Officer, Director)
Board seatAmy Schulman· per SEC Form D · $10M raise · filed Dec 2022
Co-investorsAtlas Venture
Marblehead, US
Scott Cousino(Director)Ronald Geraty(Executive Officer, Director)
Board seatAlexandra Cantley· per SEC Form D · $8.2M raise · filed Nov 2022
BiotechBurlington, US
Michael Mendelsohn(Executive Officer, Director)
BoardEvan Rachlin(Director)Peter Lawrence(Executive Officer, Director)Edward Mathers(Director)Adam Koppel(Director)inNicholas Downing(Director)
Board seatAmy Schulman· per SEC Form D · $17.5M raise · filed Dec 2022
Co-investorsBain Capital Life SciencesBain CapitalNEA SecondaryThird Rock Ventures
Dewpoint Therapeutics develops condensate-modulating drugs by using an integrated platform that maps, measures, and modulates biomolecular condensates to identify druggable targets and disease mechanisms.
AI & Machine LearningBiotechDeep TechBoston, US
Richard Young, Ph.D.(Director)Anthony Hyman, Ph.D.(Director)Tony Hyman(Scientific Co-founder)Rick Young(Scientific Co-founder)Elisabeth Leiderman(Executive Officer)Ameet Nathwani, M.D.(Executive Officer, Director)
Board seatAmir Nashat· per SEC Form D · $150M raise · filed Feb 2022
Co-investorsARCH Venture PartnersEcoR1 CapitalSamsara BioCapital6 Dimensions CapitalGeneral CatalystInnovation Endeavors+5 more
Seattle biotech that developed FDY-5301 for cardiac and skeletal muscle injury; ceased operations in February 2026.
BiotechSeattle, US
Mark Roth(Executive Officer, Director, Promoter)Brian Blackman(Executive Officer)Simon Tulloch(Executive Officer)Stephen Hill(Executive Officer, Director)
BoardPaulina Hill(Director)Steven Gillis(Executive Officer, Director, Promoter)in
Board seatTerrance McGuire· per SEC Form D · $102.8M raise · filed Nov 2022
Co-investorsARCH Venture PartnersOUP (Osage University Partners)
Podimetrics offers a virtual care service that combines remote foot monitoring with personalized support to help people with complex diabetes prevent foot complications such as amputations.
Digital HealthHealthtechMedical DevicesSomerville, US
David Linders(Executive Officer, Director)Jonathan Bloom(Executive Officer, Director)
BoardAaron Sandoski(Director)in
Board seatAlexandra Cantley· per SEC Form D · $60M raise · filed Apr 2022
Co-investorsNorwich VenturesScientific Health DevelopmentSV Health InvestorsRock Health
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.